 |
260 Diseases |  |
6 Trials |
|
6 Trials |  |
441 News |  |
| «123456 |
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, motesanib (AMG 706) / Takeda
Trial initiation date, Combination therapy, Metastases: Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - May 5, 2013
P1/2, N=0, Withdrawn, Sponsor: Thomas Jefferson University
Initiation date: Sep 2012 --> Dec 2013
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy (clinicaltrials.gov) - Apr 2, 2013
P2, N=0, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Sep 2012 --> Dec 2013 Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
New P2 trial, Metastases: Ixabepilone and SBRT For Metastatic Breast Cancer (clinicaltrials.gov) - Mar 25, 2013
P2, N=25, Recruiting, Sponsor: University of Texas Southwestern Medical Center
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: BMS-247550 in Treating Patients With Advanced Cancers (clinicaltrials.gov) - Feb 7, 2013
P1, N=54, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Avastin (bevacizumab) / Roche
Trial termination, Metastases: Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 4, 2013
P2, N=6, Terminated, Sponsor: Providence Health & Services
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of support from pharmaceutical collaborator.
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 4, 2013
P2, N=6, Terminated, Sponsor: Providence Health & Services
Recruiting --> Terminated; Lack of support from pharmaceutical collaborator. N=46 --> 6
- Enrollment closed, Metastases: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 4, 2013
P2, N=330, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=46 --> 6 Completed --> Active, not recruiting
- ||||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial initiation date, Metastases: IXAMPLE2: A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jan 31, 2013
P3, N=500, Completed, Sponsor: Bristol-Myers Squibb
Completed --> Active, not recruiting Initiation date: Jan 1996 --> Aug 2009
- || brivanib alaninate (BMS-582664) / ZAI Lab
Trial initiation date, Combination therapy, Metastases: Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (clinicaltrials.gov) - Jan 31, 2013
P1, N=189, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 1996 --> Aug 2009 Initiation date: Nov 2001 --> Mar 2009
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Avastin (bevacizumab) / Roche
Trial completion, Metastases: Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Jan 22, 2013
P2, N=82, Completed, Sponsor: SCRI Development Innovations, LLC
Initiation date: Nov 2001 --> Mar 2009 Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial termination, Combination therapy: BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Jan 15, 2013
P1, N=45, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial termination, Metastases: BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 14, 2013
P2, N=26, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Completed --> Terminated
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Herceptin (trastuzumab) / Roche
Trial termination, Combination therapy, Metastases: Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 8, 2013
P2, N=39, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Active, not recruiting --> Terminated; Slow accrual.
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial termination: BMS-247550 in Treating Patients With Liver or Gallbladder Cancer (clinicaltrials.gov) - Dec 20, 2012
P2, N=50, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Slow accrual. Completed --> Terminated
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: CALGB 40502: Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (clinicaltrials.gov) - Nov 7, 2012
P3, N=900, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Recruiting --> Active, not recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial completion, Metastases: S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction (clinicaltrials.gov) - Oct 30, 2012
P1, N=78, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial completion: BMS 247550 to Treat Kidney Cancer (clinicaltrials.gov) - Aug 12, 2012
P2, N=102, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment closed, Metastases: Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 8, 2012
P1, N=56, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment closed, Metastases: Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Aug 5, 2012
P1/2, N=85, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change, Metastases: TavIx: Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=762, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting N=2500 --> 762
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment closed, Metastases: TavIx: Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=762, Active, not recruiting, Sponsor: UNICANCER
N=2500 --> 762 Recruiting --> Active, not recruiting
- || brivanib alaninate (BMS-582664) / ZAI Lab
Enrollment closed, Combination therapy, Metastases: Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (clinicaltrials.gov) - Jun 17, 2012
P1, N=189, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion: Solid Tumors Using Ixabepilone and Dasatinib (clinicaltrials.gov) - May 28, 2012
P1, N=19, Completed, Sponsor: Washington Hospital Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Ixempra (ixabepilone) - Otsuka, R / Pharm
Enrollment closed: Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (clinicaltrials.gov) - Apr 3, 2012
P2, N=116, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial termination, Combination therapy, Metastases: UCDCC#207: Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2012
P1, N=5, Terminated, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Recruiting --> Terminated; Lack of funding
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change, Combination therapy, Metastases: UCDCC#207: Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2012
P1, N=5, Terminated, Sponsor: University of California, Davis
Recruiting --> Terminated; Lack of funding N=34 --> 5
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial withdrawal, Metastases: Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=34 --> 5 Not yet recruiting --> Withdrawn
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Withdrawn Initiation date: Jul 2008 --> Jul 2009
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Jul 2008 --> Jul 2009 N=95 --> 0
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change, Metastases: A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 1, 2012
P2, N=50, Completed, Sponsor: Bristol-Myers Squibb
N=95 --> 0 N=80 --> 50
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 1, 2012
P2, N=50, Completed, Sponsor: Bristol-Myers Squibb
N=80 --> 50 Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment closed, Metastases: Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 9, 2012
P1, N=25, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment closed: BrUOG-Pros-221: Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer (clinicaltrials.gov) - Oct 24, 2011
P2, N=16, Active, not recruiting, Sponsor: Brown University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer (clinicaltrials.gov) - Oct 13, 2011
P2, N=260, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- chloroquine phosphate / Generic mfg.
New P2 trial, Combination therapy, Metastases: Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) (clinicaltrials.gov) - Oct 2, 2011
P2, N=47, Recruiting, Sponsor: The Methodist Hospital System
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
New P1 trial: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma (clinicaltrials.gov) - Sep 27, 2011
P1, N=24, Enrolling by invitation, Sponsor: Hung-Hsueh Chou
- |||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 25, 2011
P2, N=79, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| litronesib (KF 89617) / Kyowa Kirin, Eli Lilly
New P2 trial, Metastases: A Study of LY2523355 in Participants With Breast Cancer (clinicaltrials.gov) - Aug 11, 2011
P2, N=60, Completed, Sponsor: Eli Lilly and Company